Company Research Report: CAIRDAC

Company Overview

Name: CAIRDAC

Mission: To advance cardiac rhythm management through the development of innovative, energy-efficient pacemakers that provide life-changing solutions for patients.

Founded: No information is available

Founder(s): No information is available

Key People:

Edouard Fonck - CEO

An Nguyen-Dinh - Founder, CIO

Alaa Makdissi - CTO

Willy Regnier - Industrial Executive Director

Rainer Voelksen - QA/RA Executive Director

Headquarters: No information is available

Number of Employees: The company has a multidisciplinary team of 24 focused engineers and technicians.

Revenue: No information is available

Known For: Developing the world's first autonomous leadless pacing system (ALPS™), incorporating a unique inertial energy harvesting technology synchronized with cardiac rhythm.

Products

ALPS™ (Autonomous Leadless Pacing System)

Description:

ALPS™ is a revolutionary, endoscopically implanted leadless pacemaker using a self-sustaining power technology that harvests the heart's kinetic energy.

Key Features:

Energy Harvesting Module: Utilizes a piezoelectric harvester to convert kinetic energy from the heart into electrical energy, creating a perpetual cycle that powers the device without the need for external energy sources.

Self-Sustainability: Designed for long-term use with no energy limitation; does not require replacement, reducing the complexity and cost traditionally associated with pacemaker surgeries.

Dual-Chamber Stimulation: Provides stimulation in both heart chambers, with inter-capsule communication enabled by advanced Human Body Communication transmitter technology.

Real-Time Monitoring: Equipped with monitoring capabilities that allow data collection and sharing via a holter.

Miniature Size: Allows for endoscopic implantation, significantly reducing risks such as infections associated with traditional implantation methods.

Energy Surplus & Features: Stored energy surplus supports multiple features including data storage, new sensing devices, and enhanced multi-chamber compatibility.

Recent Developments

New Products Launched: ALPS™ is under development and is currently in chronic preclinical testing phases, reporting consistent results in compatibility and performance.

New Features: ALPS™ introduces novel features such as intercommunication between heart-placed capsules and real-time data monitoring not present in existing pacemaker devices.

Partnerships: Collaborated with nine European partners, including universities and research institutes, under the Smart-MEMPHIS project to advance the development of self-powering medical devices.

Funding: Raised €17 million to finance further development of ALPS™, emphasizing the transition towards its eventual market launch targeted for 2025.

Market Position and Insights

Industry Position: CAIRDAC is positioned in a new market segment with its innovative dual-chamber, leadless pacemaker technology, offering substantial patient benefits and healthcare cost savings.

Market Growth Drivers: Addressing a market valued at approximately $3.9 billion in 2019 with a robust growth rate driven by the increasing prevalence of cardiovascular issues and the rising demand for dual-chamber leadless pacemakers.

This report synthesizes the provided data on CAIRDAC, reflecting the company's strategic advancements in medical technology through its pioneering ALPS™ system. The information demonstrates CAIRDAC's potential for growth and influence in the cardiac rhythm management sector.